Skip to main content
Poster CIO 2020-22

CIO 2020-22 Durvalumab±Bevacizumab As Adjuvant Therapy In HCC At Risk Of Recurrence After Curative Therapy: EMERALD-2

This browser does not support PDFs. Please download the PDF to view it: Download PDF.